438 results about "Tranhexamic acid" patented technology

A composition which comprises (i) tranexamic acid or a salt thereof, (ii) L-cysteine, a derivative thereof or a salt thereof and, as occasion demands, (iii) L-ascorbic acid, a derivative thereof or a salt thereof.

The invention belongs to the technical field of cosmetics and particularly relates to anti-wrinkle essence and a preparing method thereof. The anti-wrinkle essence is prepared from cyclomethicone, butanediol, polydimethylsiloxane, poly(sodium L-glutamate), glycerinum, propylene glycol, polyglycerol-10, dipropylene glycol, erythritol, hydroxyethyl acrylate / acryloyl 2 methyl taurine sodium copolymer, bio-saccharide gum, xylitol, C20-22 alcohol phosphate / C20-22 alcohol, lactic acid bacillus / pomegranate fruit extracts of fermented products, arctic rock chlamydomonas essence, starfish essence, hexapeptide-3, orange flower essence, gentian root extracts, arbutin, milk protein, tranexamic acid and the like. The anti-wrinkle essence is good in permeability and easy to absorb, effective moisturizing is achieved, skin wrinkles are repaired and inhibited from being regenerated, and skin aging is delayed.

Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

The invention discloses a whitening mask which is prepared by dipping a liquid prepared from the following raw materials in parts by weight: 0.1-3 parts of micromolecular hyaluronic acid, 0.1-2.5 parts of macromolecular hyaluronic acid, 0.7-30 parts of synthetic egg white powder, 1-7 parts of an aloe extract, 0.7-9 parts of propylene glycol, 5-50 parts of 1,2-butanediol, 5-30 parts of glycerinum, 40-80 parts of a ginseng extract liquid, 0.1-1 part of glabridin, 0.3-2 parts of alpha-arbutin, 0.1-1 part of phloretin, 0.1-1 part of apple stem cells, 1-5 parts of raspberry ketone glucoside, 0.1-1 part of tetrahydropiperine, 1-10 parts of vitamin c ethyl ether, 1-5 parts of tranexamic acid, 1-10 parts of hydrolyzed pearl and added to 1000 parts of water on mask paper. The whitening mask has the efficacies of promoting skin absorption of various effective components, repairing damaged cells, activating resting cells, promoting cell regeneration, moisturizing the skin, rapidly and efficiently whitening the skin and removing freckles, and is free of irritation, allergy or damage to the skin.

The present invention relates to compositions comprising factor VII or a factor VII-related polypeptide and tranexamic acid, and the use thereof for treating bleeding episodes.

The invention relates to a tranexamic acid skin externally applied nano-preparation, as well as a preparation method and a use thereof. The nano-preparation is prepared from tranexamic acid, medicated oil, an emulsifier, pharmaceutical additives, a thickener and pure water. The tranexamic acid skin externally applied nano-preparation provided by the invention has good physiological skin compatibility and can effectively promote the percutaneous absorption of tranexamic acid, improve the effect of preventing or treating pigmentation of the tranexamic acid and avoid toxicity and side effects, which are caused by systemic administration of the tranexamic acid.

The invention discloses a preparation method of a polypeptide silk facial mask, which comprises the steps of fully mixing polypeptide powder and silk protein nutrient solution and cooling. Polypeptide powder is mainly composed of aloe vera, carnosine, oligopeptide, soluble collagen, 2‑o‑ethyl ascorbic acid, betaine, trehalose, niacinamide, allantoin; the protein nutrient solution of silk is mainly composed of water, glycerin, Propylene glycol, butylene glycol, malto-oligosaccharide glucoside, hydrogenated starch hydrolyzate, glycerol polymethacrylate, PVM / MA copolymer, carbomer, sodium hyaluronate triethanolamine, baobab pulp extract, tranexamic acid , Centella asiatica extract, dipotassium glycyrrhizate and other skin conditioners or moisturizers. Through the combination of polypeptide powder and silk protein liquid, it can effectively give fresh nutrition to the skin, promote the skin repair process, strengthen the nutrient absorption capacity, deeply nourish, smooth and rejuvenate the skin, and make the skin elastic.

Disclosed are oral tranexamic acid formulations and methods of treatment therewith.

The invention discloses an external-use and oral-use composition. The composition comprises a tranexamic acid or a pharmaceutically-acceptable salt thereof, and a polyhydroxy acid or a pharmaceutically-acceptable salt, and also comprises polyhydric alcohol and / or a water-soluble polymer according to the condition.

The invention provides a facial mask, which contains high active ingredients, can whiten skin and improve skin tone and can sooth allergic state of skin. The facial mask comprises the following components in percentage by weight: 1-5 percent of centella, 1-5 percent of tranexamic acid, 0.2-0.8 percent of vitamin B5, 1-5 percent of vitamin B3, 1-3 percent of vitamin C, 0.2-0.8 percent of allantoin, 4-8 percent of licoflavone, 1-3 percent of glucan, 0.2-0.8 percent of sodium hyaluronate, 10-20 percent of propylene glycol, 5-15 percent of 1,3-butanediol, 0.5-1.5 percent of collagen, 1-5 percent of amino acid, 2-8 percent of witch hazel, 1-5 percent of palmitoyl pentapeptide-3, 2-8 percent of hydroxyethylurea, 0.1-0.3 percent of hydroxyethyl cellulose, 0.2-0.8 percent of azone, and 31.1-40.5 percent of deionized water.

The invention provides a full-function facial mask. The facial mask comprises the following components in percentage by mass: 0.01-2 percent of hyaluronic acid, 0.01-1 percent of reduced glutathione, 0.01-2 percent of L-vitamin C, 0.01-2 percent of tranexamic acid, 0.01-2 percent of liquiritigenin, 0.01-5 percent of vitamin E, 0.01-1 percent of EGF lyophilized powder, 0.01-2 percent of active peptide, 0.01-3 percent of SOD, 0.01-2 percent of arbutin, 0.1-2 percent of allantoin, 0.5-5 percent of glycerinum, 0.5-5 percent of propylene glycol and the balance of water, wherein the effective components are independently embedded with liposome or coated with nano-microcapsules before being mixed. The activated effective components of the facial mask are independently coated or embedded with transporters, and are delivered to the corium layer or the superficial corium layer by virtue of transportation of the transporters to achieve the effects of quadruple whitening, triple repairing and double moistening.

The invention relates to a method for preparing tranexamic acid from para-aminomethylbenzoic acid by catalytic hydrogenation. A Pt-M / C catalyst (M is selected from Ru, La, Ce, Co and Ni) is used for carrying out catalytic hydrogenation on the para-aminomethylbenzoic acid, and has the advantages of mild reaction conditions, reaction temperature of 30-60 DEG C, hydrogen pressure of 0.3-0.5MPa, high activity, reaction time of 2-4 hours, para-aminomethylbenzoic acid conversion rate up to 99 percent, tranexamic acid yield up to 95 percent, shortened reaction time, improvement of unit yield and high industrial application value.

Tranexamic acid formulated in an oral dosage form with at least one agent that decreases tranexamic acid release in the stomach. Such formulations minimize nausea, vomiting, and other adverse gastric effects that may accompany tranexamic acid therapy, for example, to treat heavy menstrual bleeding. One embodiment is an extended release formulation with waxes, polymers, etc. that prevent a bolus release of tranexamic acid in the stomach. An alternative embodiment is a delayed release formulation with polymers that prevent release of tranexamic acid in the acid environment of the stomach and delay its release until the formulation reaches the less acid environment of the intestines. Such formulations enhance patient compliance with therapy because adverse effects of tranexamic acid therapy are reduced.

The invention discloses a whitening cream and a preparing method thereof, which aims to provide a stable whitening cream with high safety, good skin whitening effect; the technical scheme is: the whitening cream is made from, by weight percentage, 0.5-0.3% of tranexamic acid, 0.5-3.5% of nicotinamide,4- 0.2-1.5% of potassium methoxysalicylate, 0.005-0.04% of glycyrrhiza glabra root extract, 0.5-2% of leucojum extract , 0.1-1.5% of saxifraga stolonifera extract, 3-6% of emulsifier, 2-5% of co-emulsifier, 10.1-23.2% of grease, 0.05-0.1% of antioxidant, 0.05-0.1% of disodium EDTA, 0.2-0.5% of allantoin, 4-10% of polyhydric alcohols, 2.25-8.55% of humectant, 0.2-0.5% of aqueous thickener, 0.5-1% of thickened stabilizer, 0.5-3% of anti-allergic conditioner, 0.8-1% of preservative, 0.5-1.2% of pigment and the margin is water; the invention belongs to the field of cosmetics technology.

The present invention provides a blood cell separation membrane for separating blood into serum or plasma and blood cells while preventing hemolysis of the blood cells. Such a blood cell separation membrane can be obtained by impregnating a porous membrane for separating blood cells from blood supplied thereto with a solution containing a hydrophobic aminocarboxylic acid, a protein derived from silk, Tris, TES, ε-aminohexanoic acid, tranexamic acid, or heparin and then drying the membrane.

In an embodiment, a method to enhance a non-surgical medical treatment, the method including applying a composition having an antifibrinolytic agent to an area of skin for non-surgical medical treatment, where the applying is at least one of before, during, and after the non-surgical medical treatment, beginning the non-surgical medical treatment to the area of skin, and continuing the non-surgical medical treatment until the non-surgical medical treatment is completed. In some embodiments, the antifibrinolytic agent is tranexamic acid in an amount of about 20% (w / v). In some embodiments, the method further includes minimizing, by the antifibrinolytic agent, bruising caused by the non-surgical medical treatment. In an additional embodiment, the present disclosure relates to a composition to enhance a non-surgical medical treatment, the composition having an antifibrinolytic agent. In a further embodiment, the present disclosure relates to a kit having a carrier and an antifibrinolytic agent.

For defects that existing hemostasis research and products cannot intelligently perform self-propelling or cannot be driven to forward deep in the wound under the action of external field force, the invention provides a preparation method for a janus structure based rapid hemostatic agent having a directional propulsion function. The preparation method includes performing esterification on microporous starch to unidirectionally grow calcium carbonate particles so as to obtain esterified microporous starch / calcium carbonate Janus particles; fixedly assembling thrombin on the surfaces of the esterified microporous starch / calcium carbonate Janus particles to obtain esterified microporous starch / calcium carbonate Janus particles assembled with the thrombin; mixing the esterified microporous starch / calcium carbonate Janus particles assembled with the thrombin and protonated tranexamic acid powder so as to obtain the janus structure based rapid hemostatic agent having a directional propulsion function. Through the formation of the biphasic heterogeneous Janus structure, the unidirectional and intelligent self-propulsion of hemostatic starch can be realized by cooperating with the protonated tranexamic acid, so that rapid three-dimensional hemostasis on deep wounds, penetrating wounds and irregular wounds such as aortic / venous rupture can be realized.

Provided is a skin external composition, which includes tranexamic acid or a salt thereof and a skin penetration enhancer, thereby showing remarkably increased skin permeability and improved sense of use, skin irritation, and storage stability.

A composition for the prevention or alleviation of pigmentation which can produce the higher effect of preventing or alleviating pigmentation. The composition for the prevention or alleviation of pigmentation comprises a combination of (A) at least one member selected from the group consisting of adenosine 5′-monophosphate and salts thereof with (B) at least one member selected from the group consisting of arbutin, ellagic acid, 4-alkylresorcinols, linoleic acid, tranexamic acid, salts of these, Chamomilla recuita extract, and Ubiquinone.

The invention discloses a moisturizing, whitening, acne removing, grease controlling and relieving skin beautifying composition. The composition is mainly prepared from the following raw materials: raspberry ketone glucoside, arbutin, matrine, fructo-oligosaccharide, tea tree oil, dipotassium glycyrrhizinate, an extracting solution of leaf of Tasmanian bluegum, tea polyphenol, a peony root extract, tremella polysaccharide, hyaluronic acid with low molecular weight, hyaluronic acid with high molecular weight, transparent xanthan gum, zinc gluconate, Carbomer 940, hydroxyethyl cellulose, 1,3-butanediol, nicotinamide, D-panthenol, tranexamic acid, vitamin C ethyl ether, triethanolamine, an emulsifier, water, and the like. The moisturizing, whitening, acne removing, grease controlling and relieving skin beautifying composition has the beneficial effects that the composition is rich in plant essence, is reasonable in proportioning and can achieve the effects of effectively comforting and smoothening pores, cleaning hair follicles, balancing grease excretion, promoting wound healing and ensuring no pockmarks after healing and low recurrence probability; besides, the composition is also rich in moisturizing ingredients, so that the skins can be hydrated and bright, fine lines can be reduced and smooth and fair skins can be restored after the composition is used for a long term.

Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.

The invention discloses a drug-delivery absorbable hemostatic sponge, which belongs to the technical field of novel hemostatic materials and comprises drug-loaded chitosan microsphere and collagen protein, wherein the drug-loaded chitosan microsphere comprises medicinal grade chitosan and medicinal grade tranexamic acid. The weight ratios of the medicinal grade chitosan to the medicinal grade tranexamic acid are (0.01-100):1 respectively. The invention also discloses a method for preparing the drug-delivery absorbable hemostatic sponge. By selecting collagen with good hemostatic function and biocompatibility as the main hemostatic substrate, compounding the drug-delivery chitosan microsphere and the medicinal grade tranexamic acid, and making use of the special properties of the chitosan including hemostatic function and drug-delivery function, a novel hemostatic sponge with rapid hemostasis and lasting and steady drug delivery in a period of time can be prepared, and has considerable economic and social benefits.

Disclosed are oral tranexamic acid formulations and methods of treatment therewith.

The invention discloses anti-allergic facial mask fluid for promoting skin regeneration. According to the anti-allergic facial mask fluid, a variety of pure natural plant extracting solutions are in combined use to achieve a certain synergistic effect, immunoregulation and inflammation prevention can be really achieved endogenously, the self-repairing ability of the skin can also be activated, and after the anti-allergic facial mask fluid is used, the skin is comfortable, no irritation can be caused, and erythema can be improved. Relative to the total mass of the facial mask fluid, the anti-allergic facial mask fluid comprises the following components in percentage by mass: 0.1-0.2% of hyaluronic acid, 0.5-1% of tranexamic acid, 0.05-0.1% of methyl hesperidin, 0.01-0.03% of carboxymethyl dextran, 2-3% of a wheat protein hydrolysate, 0.5-0.8% of a common lophatherum herb extracting solution, 1-1.5% of a baikal skullcap root extracting solution, 2.3-3% of a danshen root extracting solution, 0.3-0.5% of a fresh ginger extracting solution, 0.5% of an aloe extracting solution, 2-2.5% of a wild chrysanthemum flower extracting solution, 0.2-0.8% of a largehead atractylodes rhizome extracting solution and 0.2-0.3% of 1,2-hexanediol.

The invention belongs to the technical field of cosmetics and in particular relates to a fair-skinned, bright and white facial mask and a preparation method thereof. The fair-skinned, bright and white facial mask contains propylene glycol, hydroxyethyl urea, betaine, 3-O-ethyl ascorbic acid, arbutin, purslane extract, thyme extract, peony skin whitening essence, panthenol, nicotinamide, jojoba wax PEG-120 esters, tranexamic acid, carbomer, triethanolamine, sodium hyaluronate, PEG-40 hydrogenated castor oil, methyl hydroxybenzoate, phenoxyethanol / ethylhexyl glycerol, p-hydroxyacetophenone, essence and water. The fair-skinned, bright and white facial mask provided by the invention is natural and safe, contains multiple active ingredients, is good in permeability, can go deep into muscle bottom and supplement massive moisture and nutrients and can moisturize, nourish and repair, whiten skin, remove stains and alleviate a dark yellow state of skin, and fair-skinned and transparent skin is restored.

The invention provides whitening essence and a preparation method thereof. The whitening essence consists of the following components of glycerine, 1,3-butanediol, sodium hyaluronate, EDTA-2Na, polyglycerol-10, sodium polyacrylate, xanthan gum, hydroxyacetophenone, dipotassium glycyrrhizinate, hydrolyzed sclerotium gum, gluconic acid sodium salt, glycereth-26, caprylhydroxamic acid, glycerol caprylate, 3-o-ethyl ascorbic acid, tranexamic acid, ceramide, phenethyl resorcinol, diglucosyl gallic acid and water. The whitening essence disclosed by the invention can refrain conversion of tyrosine tomelanin before the tyrosine is in preparation of conversion to the melanin, so that the activity of the tyrosinase is also high, generation of more melanin cannot be caused, and transfer of skin melanin can also be restrained. Besides, the whitening essence has powerful antioxidant ability, has light protection effects on skin, can control dermatitis, and is a whitening product most comprehensivein action mechanism at present, so that whitening effects can be achieved.

The present invention relates to a drug delivery system for use in the treatment of vascular and vessel-related pathologies, comprising a drug delivery platform that comprises at least one compound capable of exerting an effect on the formation and / or maintenance of a thrombus in the vessel to be treated. The platform is preferably formed by liposomes that are sterically stabilized by grafting of poly(ethylene glycol) onto the liposome surface. The liposomes may further comprise photosensitizers and targeting molecules. The liposomes may be thermosensitive. The compound is suitably tranexamic acid. The drug delivery system is preferably used for the treatment of port wine stains.

The invention discloses a medicinal toothpaste composition which comprises the following raw materials in percentage by weight: 0.01%-0.05% of sodium guaiazulene sulfonate, 0.1%-0.5% of paeonol, 0.1-0.5w / w% of allantoin, 0.1-0.5w / w% of tranexamic acid, and toothpaste matrix on the basis of the total weight. In addition, the invention further discloses a preparation method of the medicinal toothpaste composition and applications in resisting bacteria, diminishing inflammation, easing pain, shortening the treatment course of dental ulcer, and promoting oral wound healing.

The present invention relates to an inhibitor for melanin which contains tranexamic acid and niacinamide as active ingredients for inhibiting the formation of melanin cells in the skin, and a cosmetic composition containing the inhibitor for melanin as an active ingredient for relieving liver spots, blemishes, freckles and inflammatory hyperpigmentation, improving skin tone and texture, and skin whitening.

A bloating ameliorant, a lymphatic vessel activator and a VEGFC production promoter comprising a tranexamic acid amide derivative and / or salt thereof.